Department of Health and Human Services July 19, 2021 – Federal Register Recent Federal Regulation Documents

Advisory Committee on Immunization Practices (ACIP)
Document Number: 2021-15322
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC), announces the following meeting of the Advisory Committee on Immunization Practices (ACIP). This meeting is open to the public. The meeting will be webcast live via the World Wide Web. Time will be available for public comment. A notice of this ACIP meeting has also been posted on CDC's ACIP website at: http://www.cdc.gov/vaccines/acip/index.html. In addition, CDC has sent notice of this ACIP meeting by email to those who subscribe to receive email updates about ACIP.
National Institute Of Environmental Health Sciences; Notice of Closed Meeting
Document Number: 2021-15312
Type: Notice
Date: 2021-07-19
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Minority Health and Health Disparities: Notice of Meeting
Document Number: 2021-15311
Type: Notice
Date: 2021-07-19
Agency: Department of Health and Human Services, National Institutes of Health
Multi-Agency Informational Meetings To Discuss Reporting Requirements for Entities; Public Webinars
Document Number: 2021-15305
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The HHS/CDC's Division of Select Agents and Toxins (DSAT) and the U.S. Department of Agriculture/Animal and Plant Health Inspection Service (APHIS)'s Division of Agricultural Select Agents and Toxins (DASAT) are jointly charged with the regulation of the possession, use and transfer of biological agents and toxins that have the potential to pose a severe threat to public, animal or plant health or to animal or plant products (select agents and toxins). This joint effort constitutes the Federal Select Agent Program. Due to the continuing pandemic and concerns for the safety of our workshop attendees and employees, DSAT replaced in-person workshops with webinars. The purpose of the webinars is to provide guidance on completing APHIS/CDC Form 2 (Request to Transfer Select Agents and Toxins), APHIS/CDC Form 3 (Report of a Release/Loss/Theft), and APHIS/ CDC Form 4 (Reporting the Identification of a Select Agent or Toxin) (APHIS/CDC Forms 2-4) for interested individuals. Two sessions covering the same agenda will be held to provide two opportunities for interested individuals to participate.
Agency Information Collection Activities: Proposed Collection; Comment Request
Document Number: 2021-15294
Type: Notice
Date: 2021-07-19
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Proposed Collection; Comment Request
Document Number: 2021-15293
Type: Notice
Date: 2021-07-19
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration
Notice of Closed Meeting
Document Number: 2021-15246
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Proposed Data Collection Submitted for Public Comment and Recommendations
Document Number: 2021-15230
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on an Extension of a previously approved information collection project titled Assessment of Occupational Injury among Fire Fighters Using a Follow-back Survey. The purpose of this project is to collect follow-back telephone interview data from injured and exposed firefighters treated in emergency departments (EDs) and produce a descriptive summary of these injuries and exposures.
Proposed Data Collection Submitted for Public Comment and Recommendations
Document Number: 2021-15229
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled the National Hospital Care Survey (NHCS). The goal of the project is to assess patient care in hospital- based settings, and to describe patterns of health care delivery and utilization in the United States.
Proposed Data Collection Submitted for Public Comment and Recommendations
Document Number: 2021-15228
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other Federal agencies the opportunity to comment on a proposed and/or continuing information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled Evaluating the use of EHMRs in health settings to improve organizational implementation and worker adoption during and after the COVID-19 pandemic. NIOSH proposes using surveys and interviews to understand how elastomeric half mask respirators (EHMRs) are being perceived and used by healthcare and first responder settings during the COVID-19 pandemic.
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2021-15227
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
Agency Forms Undergoing Paperwork Reduction Act Review
Document Number: 2021-15226
Type: Notice
Date: 2021-07-19
Agency: Centers for Disease Control and Prevention, Department of Health and Human Services
National Vaccine Injury Compensation Program; List of Petitions Received
Document Number: 2021-15223
Type: Notice
Date: 2021-07-19
Agency: Department of Health and Human Services, Health Resources and Services Administration
HRSA is publishing this notice of petitions received under the National Vaccine Injury Compensation Program (the Program), as required by the Public Health Service (PHS) Act, as amended. While the Secretary of HHS is named as the respondent in all proceedings brought by the filing of petitions for compensation under the Program, the United States Court of Federal Claims is charged by statute with responsibility for considering and acting upon the petitions.
Center for Scientific Review; Notice of Closed Meeting
Document Number: 2021-15201
Type: Notice
Date: 2021-07-19
Agency: Department of Health and Human Services, National Institutes of Health
Agency Information Collection Request; 60-Day Public Comment Request
Document Number: 2021-15172
Type: Notice
Date: 2021-07-19
Agency: Department of Health and Human Services
In compliance with the requirement of the Paperwork Reduction Act of 1995, the Office of the Secretary (OS), Department of Health and Human Services, is publishing the following summary of a proposed collection for public comment.
Product-Specific Guidance for Cilastatin Sodium; Imipenem; Relebactam; Draft Guidance for Industry; Availability
Document Number: 2021-15170
Type: Notice
Date: 2021-07-19
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Draft Guidance for Cilastatin Sodium; Imipenem; Relebactam.'' The draft guidance, when finalized, will provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs) for cilastatin sodium; imipenem; relebactam for injection.